title: CysLT2 receptors interact with CysLT1 receptors and down-modulate cysteinyl leukotriene dependent mitogenic responses of mast cells.
abstract: Cysteinyl leukotrienes (cys-LTs) induce inflammation through 2 G protein-coupled receptors (GPCRs), CysLT(1) and CysLT(2), which are coexpressed by most myeloid cells. Cys-LTs induce proliferation of mast cells (MCs), transactivate c-Kit, and phosphorylate extracellular signal-regulated kinase (ERK). Although MCs express CysLT(2), their responses to cys-LTs are blocked by antagonists of CysLT(1). We demonstrate that CysLT(2) interacts with CysLT(1), and that knockdown of CysLT(2) increases CysLT(1) surface expression and CysLT(1)-dependent proliferation of cord blood-derived human MCs (hMCs). Cys-LT-mediated responses were absent in MCs from mice lacking CysLT(1) receptors, but enhanced by the absence of CysLT(2) receptors. CysLT(1) and CysLT(2) receptors colocalized to the plasma membranes and nuclei of a human MC line, LAD2. Antibody-based fluorescent lifetime imaging microscopy confirmed complexes containing both receptors based on fluorescence energy transfer. Negative regulation of CysLT(1)-induced mitogenic signaling responses of MCs by CysLT(2) demonstrates physiologically relevant functions for GPCR heterodimers on primary cells central to inflammation.
authors: Department of Medicine, Harvard Medical School, Boston, MA, USA.
authors: Yongfeng
authors: Y
authors: Jiang
authors: Laura A
authors: LA
authors: Borrelli
authors: Yoshihide
authors: Y
authors: Kanaoka
authors: Brian J
authors: BJ
authors: Bacskai
authors: Joshua A
authors: JA
authors: Boyce
mesh_terms: D000818:Animals; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D003545:Cysteine / Q000378:metabolism / Q000494:pharmacology*; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D006367:HeLa Cells; D006801:Humans; D017998:Leukotriene D4 / Q000494:pharmacology; D015289:Leukotrienes / Q000378:metabolism / Q000494:pharmacology*; D008407:Mast Cells / Q000166:cytology / Q000187:drug effects*; D008565:Membrane Proteins / Q000235:genetics / Q000378:metabolism* / Q000502:physiology*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008938:Mitosis / Q000187:drug effects*; D011485:Protein Binding; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism; D018077:Receptors, Leukotriene / Q000235:genetics / Q000378:metabolism* / Q000502:physiology*; D015533:Transcriptional Activation / Q000187:drug effects
chemical_list: D015289:Leukotrienes; D008565:Membrane Proteins; D018077:Receptors, Leukotriene; C112381:cysteinyl-leukotriene; D017998:Leukotriene D4; C412375:cysteinyl leukotriene receptor 2; D019009:Proto-Oncogene Proteins c-kit; D048049:Extracellular Signal-Regulated MAP Kinases; D003545:Cysteine; C083169:leukotriene D4 receptor
references: Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7964-9
references: 11438743
references: J Biol Chem. 2000 Sep 29;275(39):30531-6
references: 10851239
references: J Biol Chem. 2002 Jun 7;277(23):20820-4
references: 11932261
references: Leuk Res. 2003 Aug;27(8):677-82
references: 12801524
references: J Neurosci. 2003 Jun 1;23(11):4560-6
references: 12805296
references: J Biomed Opt. 2003 Jul;8(3):368-75
references: 12880341
references: Clin Exp Allergy. 2003 Oct;33(10):1380-8
references: 14519144
references: Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11589-93
references: 13679572
references: J Neurosci. 2001 Feb 15;21(4):1203-10
references: 11160390
references: J Biol Chem. 2001 Jun 22;276(25):22608-13
references: 11319240
references: Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3047-52
references: 14970333
references: Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6587-92
references: 15084748
references: J Biol Chem. 2004 Jul 2;279(27):28756-65
references: 15123695
references: Nat Med. 2004 Oct;10(10):1065-6
references: 15448688
references: Pharmacogenetics. 2004 Sep;14(9):627-33
references: 15475736
references: J Biol Chem. 2004 Oct 29;279(44):46129-34
references: 15328359
references: Blood. 1978 Aug;52(2):447-52
references: 352443
references: J Clin Invest. 1987 Nov;80(5):1507-11
references: 3680512
references: Am Rev Respir Dis. 1992 Sep;146(3):577-80
references: 1519831
references: J Allergy Clin Immunol. 1998 Aug;102(2):177-83
references: 9723658
references: Nature. 1999 Jun 24;399(6738):789-93
references: 10391245
references: J Exp Med. 1999 Jul 19;190(2):267-80
references: 10432289
references: Autoimmun Rev. 2005 Jan;4(1):21-7
references: 15652775
references: J Allergy Clin Immunol. 2005 Feb;115(2):316-22
references: 15696087
references: Cancer Res. 2005 Feb 1;65(3):732-42
references: 15705869
references: J Immunol. 2005 Oct 15;175(8):5430-8
references: 16210650
references: Biochem Pharmacol. 2005 Dec 19;71(1-2):115-25
references: 16280122
references: J Immunol. 2006 Apr 1;176(7):4440-8
references: 16547282
references: J Immunol. 2006 May 1;176(9):5167-71
references: 16621980
references: J Clin Invest. 2006 May;116(5):1400-9
references: 16670773
references: J Immunol. 2006 Sep 1;177(5):2755-9
references: 16920908
references: EMBO J. 2006 Oct 4;25(19):4615-27
references: 16990797
references: Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16394-9
references: 17050692
references: J Allergy Clin Immunol. 2007 Jan;119(1):132-40
references: 17208594
references: J Exp Med. 2002 Mar 4;195(5):583-92
references: 11877481